SpringerLink
Log in

Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells

  • Original Manuscript
  • Published:
Leukemia Submit manuscript

Abstract

R115777, a nonpeptidomimetic farnesyl transferase inhibitor has recently demonstrated a significant antileukemic activity in vivo in acute myeloid leukemia. Multiple myeloma (MM) is a fatal hematological malignancy characterized by an accumulation of long-lived plasma cells within the bone marrow. In the present study, we have investigated the effect of the R115777 on growth and survival of myeloma cells. We have found that R115777 induced (1) a significant and dose-dependent growth inhibition of the three myeloma cell lines tested; and (2) a significant and time-dependent apoptosis. R115777 also induced apoptosis in the bone marrow mononuclear cell population of four MM patients, being almost restricted to the malignant plasma cells. Finally, we have investigated the effect of the R115777 in the Ras/MAPK and JAK/STAT pathways which are implicated in survival and/or proliferation in MM. The phosphorylation of both STAT3 and ERK1/2 induced by IL-6 was totally blocked at 15 μM of R115777 and partially blocked when R115777 was used at 10 and 5 μM. The induction of apoptosis by R115777 in myeloma cells and its implication in the regulation of JAK/STAT signalling suggest that R115777 might be an interesting therapeutical approach in MM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Bataille R, Harousseau J-L . Multiple myeloma N Engl J Med 1997 336: 1657–1664

    Article  CAS  Google Scholar 

  2. End DW, Smets G, Todd AV, Applegate TL, Fuery CJ, Angibaud P, Venet M, Sanz G, Poignet H, Skrzat S, Devine A, Wouters W, Bowden C . Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro Cancer Res 2001 61: 131–137

    CAS  PubMed  Google Scholar 

  3. Zujewski J, Horak ID, Bol CJ, Woestenborghs R, Bowden C, End DW, Piotrovsky VK, Chiao J, Belly RT, Todd A, Kopp WC, Kohler DR, Chow C, Noone M, Hakim FT, Larkin G, Gress RE, Nussenblatt RB, Kremer AB, Cowan KH . Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer J Clin Oncol 2000 18: 927–941

    Article  CAS  Google Scholar 

  4. Punt CJ, van Maanen L, Bol CJ, Seifert WF, Wagener DJ . Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors Anticancer Drugs 2001 12: 193–197

    Article  CAS  Google Scholar 

  5. Kelland LR, Smith V, Valenti M, Patterson L, Clarke PA, Detre S, End D, Howes AJ, Dowsett M, Workman P, Johnston SR . Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer Clin Cancer Res 2001 7: 3544–3550

    CAS  Google Scholar 

  6. Karp JE, Lancet JE, Kaufmann SH, End DW, Wright JJ, Bol K, Horak I, Tidwell ML, Liesveld J, Kottke TJ, Ange D, Buddharaju L, Gojo I, Highsmith WE, Belly RT, Hohl RJ, Rybak ME, Thibault A, Rosenblatt J . Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial Blood 2001 97: 3361–3369

    Article  CAS  Google Scholar 

  7. Karp JE . Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies Semin Hematol 2001 38: 16–23

    Article  CAS  Google Scholar 

  8. Sepp-Lorenzino L, Ma Z, Rands E, Kohl NE, Gibbs JB, Oliff A, Rosen N . A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines Cancer Res 1995 55: 5302–5309

    CAS  Google Scholar 

  9. Cox AD, Der CJ . Farnesyl inhibitors and cancer treatment: targeting symply Ras? Biochim Biophys Acta 1997 1333: F51–F71

    CAS  PubMed  Google Scholar 

  10. Lebowitz PF, Prendergast GC . Non-Ras targets of farnesyltransferase inhibitors: focus on Rho Oncogene 1998 17: 1439–1445

    Article  CAS  Google Scholar 

  11. Law BK, Norgaard P, Moses HL . Farnesyltransferase inhibitor induces rapid growth arrest and blocks p70s6k activation by multiple stimuli J Biol Chem 2000 275: 10796–10801

    Article  CAS  Google Scholar 

  12. Jiang K, Coppola D, Crespo NC, Nicosia SV, Hamilton AD, Sebti SM, Cheng JQ . The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis Mol Cell Biol 2000 20: 139–148

    Article  Google Scholar 

  13. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H . Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas Nature 1988 332: 83–85

    Article  CAS  Google Scholar 

  14. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L . Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway Biochem J 1998 334: 297–314

    Article  CAS  Google Scholar 

  15. Ogata A, Chauhan D, Teoh G, Treon SP, Urashima M, Schlossman RL, Anderson KC . IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade J Immunol 1997 159: 2212–2221

    CAS  PubMed  Google Scholar 

  16. Puthier D, Bataille R, Amiot M . IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway Eur J Immunol 1999 29: 3945–3950

    Article  CAS  Google Scholar 

  17. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, Dalton WS, Jove R . Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells Immunity 1999 10: 105–115

    Article  CAS  Google Scholar 

  18. De Vos J, Jourdan M, Tarte K, Jasmin C, Klein B . JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells Br J Haematol 2000 109: 823–828

    Article  CAS  Google Scholar 

  19. Bezieau S, Devilder MC, Avet-Loiseau H, Mellerin MP, Puthier D, Pennarun E, Rapp MJ, Harousseau J-L, Moisan JP, Bataille R . High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis Hum Mutat 2001 18: 212–224

    Article  CAS  Google Scholar 

  20. Durie BG . Staging and kinetics of multiple myeloma Semin Oncol 1986 13: 300–309

    CAS  Google Scholar 

  21. Puthier D, Bataille R, Barille S, Mellerin MP, Harousseau JL, Ponzio A, Robillard N, Wijdenes J, Amiot M . Myeloma cell growth arrest, apoptosis, and interleukin-6 receptor modulation induced by EB1089, a vitamin D3 derivative, alone or in association with dexamethasone Blood 1996 88: 4659–4666

    CAS  PubMed  Google Scholar 

  22. Koester SK, Roth P, Mikulka WR, Schlossman SF, Zhang C, Bolton WE . Monitoring early cellular responses in apoptosis is aided by the mitochondrial membrane protein-specific monoclonal antibody APO2.7 Cytometry 1997 29: 306–312

    Article  CAS  Google Scholar 

Download references

Acknowledgements

SL is supported by the Association pour la Recherche sur le cancer.

Author information

Authors and Affiliations

  1. Institut National de la Santé et de la Recherche Médicale Unité 463, Institut de Biologie, Nantes, France

    S Le Gouill, C Pellat-Deceunynck, R Bataille & M Amiot

  2. Service d'Hématologie Biologique, Nantes, France

    N Robillard

  3. Service d'Hématologie Clinique, Nantes, France

    J-L Harousseau & M-J Rapp

Authors
  1. S Le Gouill
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C Pellat-Deceunynck
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J-L Harousseau
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M-J Rapp
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N Robillard
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R Bataille
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Amiot
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Le Gouill, S., Pellat-Deceunynck, C., Harousseau, JL. et al. Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells. Leukemia 16, 1664–1667 (2002). https://doi.org/10.1038/sj.leu.2402629

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2402629

  • Springer Nature Limited

Keywords

Search

Navigation